We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
Turnover
18.82%
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+5.13%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$319M
AUM Growth
+$18.9M
(+6.3%)
Cap. Flow
+$6.94M
Cap. Flow
% of AUM
2.17%
Top 10 Holdings %
Top 10 Hldgs %
37.77%
Holding
106
New
6
Increased
17
Reduced
26
Closed
10
Avg Time Held
3.1
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$6.87M |
| 2 |
IBM
IBM
|
+$6.33M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$3.96M |
| 4 |
Stryker
SYK
|
+$2.76M |
| 5 |
Cigna
CI
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$3.67M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$1.74M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$1.38M |
| 4 |
KKR & Co
KKR
|
+$1.27M |
| 5 |
Targa Resources
TRGP
|
+$841K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.66% |
| 2 | Technology | 16.82% |
| 3 | Communication Services | 16.5% |
| 4 | Industrials | 8.67% |
| 5 | Miscellaneous | 6.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Fiserv Inc
FISV
$25.2B
| $904K | 0.28% |
12,200
| – | – |
2013 Q2
20 quarters
|
|
52
Johnson & Johnson
JNJ
$615B
| $811K | 0.25% |
6,682
| – | – |
2013 Q2
20 quarters
|
|
53
Coca-Cola
KO
$401B
| $789K | 0.25% |
18,000
| – | – |
2013 Q2
20 quarters
|
|
54
Ball Corp
BALL
$16.7B
| $720K | 0.23% |
20,260
| – | – |
2013 Q2
20 quarters
|
|
55
T. Rowe Price
TROW
$21.4B
| $688K | 0.22% |
5,930
| – | – |
2013 Q2
20 quarters
|
|
56
Liberty Media Corporation Series A Common Stock
FWONA
$20.7B
| $654K | 0.2% |
19,332
-208
| -1% | -$6K |
2016 Q3
7 quarters
|
|
|
FSTX
57
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $620K | 0.19% |
13,084
| – | – |
2017 Q1
5 quarters
|
|
|
MDSO
58
DELISTED
Medidata Solutions, Inc.
MDSO
| $596K | 0.19% |
7,400
| – | – |
2013 Q3
19 quarters
|
|
59
Gilead Sciences
GILD
$193B
| $581K | 0.18% |
8,207
| – | – |
2013 Q2
20 quarters
|
|
60
Parker-Hannifin
PH
$121B
| $581K | 0.18% |
3,727
| – | – |
2013 Q2
20 quarters
|
|
|
LLL
61
DELISTED
L3 Technologies, Inc.
LLL
| $577K | 0.18% |
3,000
| – | – |
2013 Q2
20 quarters
|
|
62
CVS Health
CVS
$119B
| $544K | 0.17% |
8,450
| – | – |
2013 Q2
20 quarters
|
|
63
American Electric Power
AEP
$69.1B
| $541K | 0.17% |
7,810
| – | – |
2013 Q2
20 quarters
|
|
|
CORI
64
DELISTED
Corium International, Inc.
CORI
| $521K | 0.16% |
+65,000
| New | +$615K |
2018 Q2
0 quarters
|
|
65
Tesla
TSLA
$1.39T
| $520K | 0.16% |
+22,725
| New | +$462K |
2018 Q2
0 quarters
|
|
66
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $485K | 0.15% |
14,049
| – | – |
2016 Q2
8 quarters
|
|
67
DELISTED
Liberty Broadband Class A
LBRDA
| $440K | 0.14% |
5,819
-199
| -3% | -$15K |
2014 Q4
14 quarters
|
|
68
Liberty Media Corporation Series C Common Stock
FWONK
$22.6B
| $428K | 0.13% |
11,916
-414
| -3% | -$12.6K |
2014 Q3
15 quarters
|
|
|
ETP
69
DELISTED
Energy Transfer Partners, L.P.
ETP
| $423K | 0.13% |
22,240
-3,300
| -13% | -$60.6K |
2017 Q1
5 quarters
|
|
70
Microsoft
MSFT
$3.91T
| $395K | 0.12% |
4,003
| – | – |
2013 Q2
20 quarters
|
|
71
Texas Instruments
TXN
$255B
| $383K | 0.12% |
3,475
| – | – |
2016 Q2
8 quarters
|
|
|
DISH
72
DELISTED
DISH Network Corp.
DISH
| $355K | 0.11% |
10,550
| – | – |
2013 Q2
20 quarters
|
|
73
Ingevity
NGVT
$2.41B
| $335K | 0.11% |
4,147
| – | – |
2016 Q4
6 quarters
|
|
74
State Street Health Care Select Sector SPDR ETF
XLV
$45.7B
| $334K | 0.1% |
4,000
| – | – |
2013 Q3
19 quarters
|
|
75
Goldman Sachs
GS
$256B
| $314K | 0.1% |
1,425
| – | – |
2013 Q2
20 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Private Capital Advisors held 106 positions worth $319M, up 6.3% from $300M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Private Capital Advisors's Q2 2018 filing shows 6 new, 17 increased, 26 reduced and 10 closed positions. Its largest new stake was Karyopharm Therapeutics: 27,793 shares worth $7.08M. The largest sale was Meta Platforms (Facebook), an estimated $3.67M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.
- Private Capital Advisors's largest Q2 2018 buy was Karyopharm Therapeutics: 27,793 shares worth $7.08M.
- Private Capital Advisors added most to IBM in Q2 2018, an estimated $6.33M increase.
- Private Capital Advisors's biggest Q2 2018 reduction was Meta Platforms (Facebook), cutting an estimated $3.67M.
- Private Capital Advisors fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $1.74M.
- Private Capital Advisors's ten largest holdings make up 38% of its $319M portfolio in Q2 2018.
- Private Capital Advisors opened 6 new positions and closed 10 in Q2 2018.
- Private Capital Advisors's portfolio value rose 6.3% quarter-over-quarter to $319M.
Based on Private Capital Advisors's 13F filing for Q2 2018, filed 10 Jul 2018.